China breaks the monopoly of foreign patented drugs in the fields of lung cancer and leukemia, and the creation of new drugs welcomes the "bumper harvest"
Lung cancer, leukemia and other fields broke foreign monopolies, and the listing of domestic small molecule targeted drugs promoted the price reduction of foreign drugs in China by more than 50%... The major national scientific and technological achievements include not only 4G mobile communication and Beidou satellite navigation, but also biomedical technology innovations closely related to the health of the people.
The reporter learned at the "National Science and Technology Major Special Project for the Creation of New Drugs" held by the Ministry of Science and Technology on the 22nd that China has broken the monopoly of foreign drugs in the fields of lung cancer, leukemia and drug-resistant bacteria, and the research and development innovation capabilities and industrial development of the biomedical industry have been continuously enhanced, and the stage results have been achieved and fruitful.
The drug problem is related to the life and health of the people, and there have been painful lessons all over the world, and non-clinical evaluation is an important part of the necessary stage of new drug research and development. Sang Guowei, chief technical engineer of new drug creation and academician of the Chinese Academy of Engineering, said that with the special support of new drug creation, a series of major breakthroughs have been made in the construction of China's non-clinical evaluation platform for drugs, the preclinical evaluation of new drugs has been in line with international standards, and the core key technologies of the evaluation platform have reached the international advanced level, which has strongly supported the research and development of new drugs in China and ensured public drug use.
In order to implement the requirements of the General Office of the CPC Central Committee and the General Office of the State Council on Deepening the Reform of the Review and Approval System and Encouraging the Innovation of Drugs and Devices, the CFDA organized and drafted the Announcement on Adjusting the Review and Approval of Drug Clinical Trials (Draft for Comments), which is now open for comments and suggestions.
In order to ensure the quality of non-clinical evaluation research of drugs and protect public use, the State Food and Drug Administration recently issued the newly revised "Good Management Practice for Non-clinical Research of Drugs" (Order No. 34 of the State Food and Drug Administration) (hereinafter referred to as the "Specification")
After combing, we found that in the list of the top 2000, 54 companies in the pharmaceutical industry are among them, accounting for 2.7% of the total. Unsurprisingly, Johnson & Johnson topped the list with a market cap of $275.7 billion, while it ranked 34th